Document is current
Any future updates will be listed below
-
Authors
Thompson, Peter J. https://orcid.org/0000-0002-6851-8899
Pipella, Jasmine https://orcid.org/0009-0005-9936-8386
Rutter, Guy A. https://orcid.org/0000-0001-6360-0343
Gaisano, Herbert Y. https://orcid.org/0000-0001-5213-9168
Santamaria, Pere https://orcid.org/0000-0003-3469-1586
-
Funding
Funding for this research was provided by:
FEDER
Research Manitoba (5351)
Health Sciences Centre Foundation Winnipeg
NIH-NIDDK (R01DK135268)
Canadian Institutes of Health Research (CIHR-IRSC TDP-186358, FDN-353029, FRN-168480, PJT-479038, PJT-479040, PJT-479641)
End Diabetes 2022 Award from Diabetes Canada (OG-3-22-5694-PT)
Genome Canada
Wellcome Trust Investigator Award (212625/Z/18/Z)
Innovation Canada John R. Evans Leader Award (CFI 42649)
Red Española de Supercomputación
CRCHUM start-up funds
UK MRC Programme grant (MR/R022259/1)
Juvenile Diabetes Research Foundation United States of America (DT4-179512, JDRF 4-SRA-2023-1182-S-N)
Diabetes UK Project grant (BDA16/0005485)
ISCIII and FEDER (PI15/0797, PIE14/00027)
Praespero
MINECO (PID2021-125493OB-I00)
Generalitat de Catalunya
Alberta Diabetes Foundation
- License Information
-
More Information
Article History
Received: 10 March 2023
Accepted: 30 May 2023
First Online: 25 July 2023
Acknowledgements
: We apologise to colleagues whose work could not be cited due to space limitations.
: PJT was supported by CIHR (PJT-479641), a new investigator operating grant from Research Manitoba (5351), an operating grant from the Health Sciences Centre Foundation Winnipeg and an End Diabetes 2022 Award from Diabetes Canada (OG-3-22-5694-PT). GAR was supported by a Wellcome Trust Investigator Award (212625/Z/18/Z), UK MRC Programme grant (MR/R022259/1), Diabetes UK Project grant (BDA16/0005485), CRCHUM start-up funds, an Innovation Canada John R. Evans Leader Award (CFI 42649) and NIH-NIDDK (R01DK135268) project grant. HYG was supported by CIHR (PJT-159741 and PJT-148652) and the Canada Research Chairs Program. PS was supported by CIHR (FDN-353029, PJT-479040, PJT-479038, FRN-168480 [with JDRF], DT4-179512), Genome Canada (GAPP program), the Praespero Foundation, the Alberta Diabetes Foundation, the ISCIII and FEDER (PIE14/00027, PI15/0797), MINECO (PID2021-125493OB-I00), Generalitat de Catalunya (SGR and CERCA Programmes) and Red Española de Supercomputación (RES, providing CSUC resources). All investigators were supported by a CIHR-JDRF team grant (CIHR-IRSC TDP-186358 and JDRF 4-SRA-2023-1182-S-N).
: GAR has received grant funding from, and is a consultant for, Sun Pharmaceuticals Inc. PS is founder, scientific officer and stockholder of Parvus Therapeutics. He is inventor on patents on pMHC-based nanomedicines and receives funding from the company. The other authors declare that there are no relationships or activities that might bias, or be perceived to bias, their work.
: All authors conceived of the manuscript and provided contributions. PJT and PS wrote the sections on islet autoimmunity initiation, antigen presentation and early life exposures. JP wrote the section on beta cell stress pathways with guidance from PJT. GAR wrote the section on beta cell functional heterogeneity. HYG wrote the section on alpha cell dysfunction. All authors edited and approved the final version of the manuscript.
